Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alza Concerta Climbs To 15% Of ADHD Market With 170,000 Patients

Executive Summary

Alza Concerta holds 15% of the attention deficit hyperactive disorder market, Senior VP-Sales & Marketing Dan Swisher told the company's annual analyst meeting in New York City Feb. 27.

You may also be interested in...



Celltech Metadate CD Shows Morning/Afternoon Control Of ADHD, Label Says

Celltech Metadate CD given once daily demonstrates control of attention deficit hyperactivity disorder early and late in the school day, product labeling notes.

Celltech Metadate CD Shows Morning/Afternoon Control Of ADHD, Label Says

Celltech Metadate CD given once daily demonstrates control of attention deficit hyperactivity disorder early and late in the school day, product labeling notes.

Alza Concerta Marketing May Expand ADHD Market, Aid Adderall - Shire CEO

Shire sees preliminary evidence that Alza's marketing of Concerta could expand the ADHD market for Adderall, CEO Rolf Stahel said during an Oct. 31 conference call.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel